Deep Investment Research: Nobel Prize-Winning Gene Editing Therapy, Why Is the Market Only Valuing It at a Quarter of Its Price?

A simple arithmetic problem:
CRISPR Therapeutics has a current market cap of $4.5 billion. Cash on hand is $2.5 billion. $4.5 billion - $2.5 billion = $2 billion.
What is the market pricing at $2 billion?
The world's first FDA-approved CRISPR gene editing therapy + 6 active clinical pipelines + Nobel Prize-level intellectual property + exclusive partnership with Vertex, valued at $110 billion.
But rebuilding these assets from scratch would cost at least $7.2 billion.
This article clarifies one thing: what exactly does this $2 billion buy, and is it worth it?
1. What is Casgevy?
The first FDA-approved CRISPR gene editing therapy in human history.
It treats SCD (sickle cell disease)—patients' red blood cells turn into sickle shapes, blocking blood vessels, causing severe pain, repeated hospitalizations, and organ damage. There are 20 million patients worldwide, with an average lifespan 20-30 years shorter, and lifetime medical costs of $1.6-6 million.
Casgevy's principle: extract hematopoietic stem cells from the patient → use CRISPR/Cas9 to edit a gene → reactivate "fetal hemoglobin" → re-infuse into the body → the body begins producing normal hemoglobin itself.
One treatment. Cures from the root.
Clinical data: 45/45 SCD patients (100%) experienced no pain crises for 12 months+ after treatment. Longest follow-up over 6 years, with sustained effects.
Priced at $2.2 million per person. Sounds exorbitant, but compared to lifelong treatment costs of $1.6-6 million, it's a cost-effective deal. ICER evaluation indicates costs below $2.05 million are cost-effective. CMS (Centers for Medicare & Medicaid Services) has launched outcome-based payment agreements in 33 states.
2. Commercialization progress
Casgevy is being commercialized globally by Vertex Pharmaceuticals (market cap $110 billion), which holds a monopoly on CF treatments, with CRSP sharing 40% of profits.
FY2025 results:
Global sales of $115.8 million (a 10x increase from FY2024's $10 million)
Q4 single-quarter $54 million, doubling quarter-over-quarter
64 patients completed infusion, 301 initiated treatment
75+ authorized treatment centers activated
Approximately 90% of US patients covered by insurance
Patient cell collection in 2025 is three times that of 2024
Analysts expect FY2026 sales of $230-340 million. William Blair estimates peak sales at $3.6 billion.
3. Not just a product—6 pipelines
Most people only know Casgevy. But CRSP actually has a multi-pipeline platform spanning oncology, autoimmune, cardiovascular, and diabetes:
Zugo-cel (allogeneic CAR-T): targeting CD19, treating B-cell malignancies + autoimmune diseases. ORR at RP2D dose is 90% (9 out of 10 patients effective), granted FDA's RMAT designation (Regenerative Medicine Advanced Therapy, accelerated approval). The first SLE (lupus) patient achieved complete remission within 6 months—no medication maintenance needed.
CTX310 (in vivo gene editing): targeting ANGPTL3 to lower triglycerides and LDL cholesterol. Data published in The New England Journal of Medicine—TG down 55%, LDL down 49%. This marks a key step for CRISPR therapy entering the "large cardiovascular market."
CTX211 (Type 1 Diabetes): gene-edited stem cell-derived pancreatic beta cells. If successful, 8.7 million T1D patients worldwide might no longer need lifelong insulin injections.
2026 catalysts include: H1 Casgevy pediatric global filings / H1 CTX340 (hypertension) clinical initiation / H2 Zugo-cel multi-indication data / H2 CTX310 Phase 1b update.
4. Why conduct a reset cost analysis?
Traditional valuation methods (P/E, P/S, DCF) are nearly useless for loss-making biotech companies—CRSP's FY2025 net loss is $582 million, with no positive profit to base on.
So I asked a more fundamental question: how much would it cost to rebuild a CRISPR Therapeutics from zero?
Key benchmark data:
Springer’s 2023 peer-reviewed study analyzed 11 approved cell/gene therapies, concluding that taking a new CGT from clinical stage to FDA approval costs an average of $4.5B in R&D.
Evernorth is more aggressive—average R&D costs for gene therapies are about $5 billion.
More critically, FDA data shows that the probability of a Phase 1 drug ultimately getting approved is only 13.8%.
What does this mean? To reset a Casgevy, you need to start 7-8 parallel projects on average, bearing 6-7 failures.
5. Itemized reset of seven asset categories
Asset Category Conservative Neutral Rebuild Time
① Casgevy (approved) $2.2B $3.95B 8-12 years
② Clinical pipelines (6+ pipelines) $700M $1B 3-8 years
③ GMP manufacturing facilities $140M $200M 2-3 years
④ CRISPR/Cas9 IP + SyNThase $550M $800M Non-replicable
⑤ Vertex partnership $600M $800M 3-5 years
⑥ 6 years of clinical data + 75 treatment centers $330M $500M 6-10 years
⑦ Talent team $100M $150M 2-3 years
Adjusted reset costs (including clinical failure risk, time premium, IP non-replicability premium):
Scenario Reset Cost vs Market Cap $4.5B
Conservative $7.2B 60% premium
Neutral $13.3B 196% premium
Even the most conservative estimate of $7.2 billion exceeds the current market cap by 60%. The market only values it at 60% of the reset cost.
A more extreme comparison: after deducting $2.5 billion in cash, implied pipeline valuation is only $2 billion—yet the neutral reset cost for Casgevy alone is $3.95 billion.
6. Three non-replicable barriers
First, 86% of failures have been overcome.
86% of gene therapies entering Phase 1 will fail along the way. Casgevy is among the 14% survivors. From the 2015 Vertex partnership, 2018 patient enrollment, to FDA approval in 2023, it took 8 years. This "realized option" value is billions—because you cannot buy the 86% failure rate that never materializes.
Second, the invention of CRISPR/Cas9 is non-replicable.
Emmanuelle Charpentier won the 2020 Nobel Prize in Chemistry for discovering CRISPR/Cas9. This is a fundamental scientific breakthrough—not an engineering optimization—you can spend money to build labs, hire scientists, conduct trials, but you cannot "re-invent" CRISPR/Cas9. Charpentier’s exclusive licensing of CRSP is an IP asset without a second copy on Earth.
Third, 6 years of human gene editing safety data.
For a one-time, permanent human genome change, the biggest concern for doctors is "Is it safe after 10 years?" Casgevy has the longest human follow-up record among CRISPR therapies globally—and each additional year of data deepens its moat. Even if competitors like Beam’s BEAM-101 get approval tomorrow, they will need to start from zero to accumulate long-term data.
7. Cross-validation of 10 valuation methods
Method Implied Target Price
Cash Adjustment Method $26 (bottom, cash=$26/share)
Casgevy rNPV $26-54
Segment Valuation SoTP $57-94
DCF $55-75
EV/Peak Sales ~$CRSP Reset Cost Method (conservative) $75 ($7.2B ÷ 96 million shares)
Reset Cost Method (neutral) $139 ($13.3B ÷ 96 million shares)
Analyst Consensus $70-83
ARK Implied Long-term $150+
Short-squeeze potential $60-80
Including the reset method, the median valuation across 10 methods is about $65-70, with the current price at $47, implying about 35-50% upside.
17 analysts: 11 buy / 6 hold / 0 sell. Highest target $110 by Piper Sandler.
8. Risks cannot be ignored
Risk 1: Beam Therapeutics’ base editing platform. BEAM-101 also targets SCD, with base editing avoiding double-strand DNA breaks, theoretically safer. More importantly, Beam’s ESCAPE platform aims to replace chemotherapy preconditioning with antibodies—if successful, it will drastically change the competitive landscape for SCD gene therapy. This is the most significant long-term threat to watch.
Risk 2: Commercialization ramp-up pace. FY2025 infusion count is only 64 vs 301 initiated, with a conversion rate of about 21%. Chemotherapy preconditioning is the biggest obstacle—patients need months of preparation, long hospital stays, and face fertility risks. The $2.2 million price also complicates reimbursement processes.
Risk 3: Still deep in losses. FY2025 net loss is $582 million. Although with $2.5 billion cash (6-7 years runway), profitability is still 5-7 years away.
9. Conclusion
CRSP’s current price of $47 essentially boils down to this arithmetic:
You buy at $47/share (market cap $4.5 billion). Of this, $2.6/share ($2.5 billion) is cash—money sitting in the bank, not disappearing.
The remaining $2.1/share ($2 billion), you get:
The world’s first FDA-approved CRISPR gene editing therapy (reset cost $2.2-3.95 billion)
6 active clinical pipelines (including ORR 90% CAR-T + NEJM-published cardiovascular pipeline)
Nobel Prize-level non-replicable IP
Exclusive profit-sharing partnership with a $110 billion pharma company
6 years of human gene editing safety data
Institutional support from Ark and others holding about 11% of circulating shares
$2 billion to buy in, but rebuilding would cost at least $7.2 billion.
Downside: $2.6/share cash provides 45% downside protection. Upside: analyst consensus $70-83 (+50-75%), with pipeline catalysts intensifying (H2 2026).
86% clinical failure rate has been overcome, Nobel-level IP cannot be re-invented, and 6 years of safety data daily deepen the moat.
The market only gives a 25% discount. Your only task is to judge one thing: is this gene editing revolution real or fake?
⚠️: This article is solely a personal investment research sharing and does not constitute any investment advice!